The loading of nucleic acids by glyconanoparticles represents an innovative and promising area in the field of nanotechnology. Glyconanoparticles offer several advantages for nucleic acid loading. They provide a stable and protected microenvironment, reducing the degradation and inactivation of nucleic acids. The load of nuclear acid to glyconanoparticle also enables targeted delivery of nucleic acids to specific cells or tissues, increasing the specificity and reducing off-target effects. The interaction between the glyconanoparticles and the nucleic acids is finely tuned to optimize loading efficiency and controlled release. Moreover, the physicochemical properties of the nanoparticles can be modulated to improve their biocompatibility and pharmacokinetic profiles. Furthermore, the loaded nucleic acids can be precisely targeted to specific cells or tissues, improving the therapeutic efficacy and minimizing side effects. The controlled release of nucleic acids from the glyconanoparticles can also be achieved, allowing for timed and sustained delivery. This technology holds great potential in applications such as gene therapy, cancer treatment, and the development of novel diagnostic tools.
CD BioGlyco possesses an advanced and cutting-edge GlycoNano™Platform that is fully equipped and operational. This encompasses not only one-stop Glyconanoparticle Development but also meticulous Glyconanoparticle Formulation. Moreover, we provide precise Characterization and thorough Preclinical Study services. The aim is to ensure that customers receive holistic and professional support throughout the entire process, meeting their diverse and specific requirements with the highest standards of quality and efficiency. Our nucleic acid-loaded glyconanoparticle formulation service includes but is not limited to the following.
First, gold nanoparticles (AuNPs) are synthesized by sodium tetrachloroaurate(III) hydrate and sodium citrate. The synthesized AuNPs are then stabilized with polyvinyl alcohol (PEG) and subsequently functionalized. Usually, we use two types of mercaptan PEG (such as commercialized carboxyl PEG and laboratory-synthesized PEG with azide groups) for surface coating. Then, through the EDC coupling reaction, amino-modified biotin and glucose are connected to the surface of AuNPs to form an amide bond. Finally, we make the nucleic acid connection. Using mercaptan nucleic acids, the efficient attachment of the nucleic acid is ensured by directly linking the mercaptan group to the gold core (Au) to form a strong pseudo-covalent bond (AU-S) to function within the cell.
We observe the morphology and particle size distribution of nanoparticles by using transmission electron microscopy (TEM) or scanning electron microscopy (SEM). This can help to confirm that the size and shape of the nanoparticles are as expected. The ζ-potential of the nanoparticles is measured by dynamic light scattering (DLS) to assess their surface charge and stability. Surface charge has an important effect on the distribution and interaction of nanoparticles in living organisms. Techniques such as ultraviolet-visible spectroscopy (UV-Vis) and Fourier transform infrared spectroscopy (FTIR) are used to confirm the successful attachment of functional groups such as sugar, PEG, and siRNA.
Technologies: Bioluminescence imaging, Immunohistochemical staining, Cell counting and differentiation
Journal: Nanoscale
Published: 2015
IF: 5.79
Results: The main research of this article is to investigate RNA interference (RNAi)--based sugar nanoparticles (GlycoNPs) in cancer cell killing. It was shown that siRNA GlycoNPs (AuNP@PEG@Glucose@siRNA) could effectively induce apoptosis in cancer cells. Specifically, siRNA GlycoNPs exhibited dose-dependent apoptosis induction in vitro and in vivo by enhancing the expression of cell death receptors (e.g., Fas/CD95) and activating apoptosis-associated cysteoaspartic enzymes. This effect was independent of the inflammatory response, suggesting that siRNA GlycoNPs are capable of specifically triggering the apoptotic pathway without inducing an adverse inflammatory response. In in vivo experiments, siRNA GlycoNPs administered through the lungs were able to target the expression of the c-Myc gene, leading to a reduction in tumor size of approximately 80%. This suggests that siRNA GlycoNPs have significant potential in cancer therapy and can effectively inhibit tumor growth through the RNAi mechanism.
Fig.1 Multifunctional siRNA GlycoNPs initiate apoptotic pathways and gene silencing. (Conde, et al., 2015)
CD BioGlyco meticulously handles every step of the process of nucleic acid-loaded glyconanoparticle formulation service, from the selection of optimal materials to the precise control of formulation parameters. We focus on maximizing the loading efficiency of nucleic acids, enhancing the stability and bioavailability of the nanoparticles, and tailoring the properties to suit your targeted applications. If you are interested in our service, please feel free to contact us!
Reference